The people at the heart of AI in healthcare
Optimize MSI testing through a pre-screen approach
Assess the risk of relapse of early breast cancer
Ability to access and leverage routine digital pathology images in our AI models to prevent expensive and time consuming screening techniques.
Allowing expert validation and continuous improvement of model performance.
Renowned AI expertise with # published papers in leading journals, two strategic alliances with leading biopharma companies, and AI digital pathology diagnostics.
De-risk early clinical trials
Owkin synthetic control arms increase the confidence in value of a single arm trial.
Identify prognostic signal
Evidence-based covariate adjustment to improve trials.